All times shown in GMT - please see the Full Event Guide for CET
8:30 am Virtual Coffee Networking Rooms
9:00 am Chair’s Opening Remarks
9:15 am Industry Leader’s Fireside Chat
10:00 am Discussing Progress, Success, and Future Development in Allogeneic CAR-TCR Cell Therapies
10:30 am Morning Refreshments & Speed Networking
Research & Development
Translation & Clinical
Manufacturing & Commercialisation
Breakthroughs in Solid Tumours: Expanding CAR-TCR Indications
Characterising Cell Types to Select for Highly Efficacious, Cost-Effective Products
Improving Access to CAR-TCR Across Europe
11.00 Developing a qCART Platform to Produce Virus-Free Optimal CAR-T Systems
To see full session details, download the full event guide
Sareina Wu, CEO & CSO, GenomeFrontier Therapeutics
11.00 Providing Mechanistic Rationale
for Combination Therapies Through Functional Characterisation
To see full session details, download the full event guide
Marc Van Dijk, CTO, Agenus
11.00 Implications of Varied Regulatory
Standards and Hospital Exemption Rules on Drug Product Safety and Commercial Ability
To see full session details, download the full event guide
Annie Hubert, Senior Director, Section & Public Policy, Alliance for Regenerative Medicine
11.30 Equipping T Cells for Trafficking,
Persistence and Maximum Efficacy in the Solid Tumour Setting
To see full session details, download the full event guide
Dolores Schendel, CEO & CSO, Medigene AG
11.30 Improving In Vivo Efficacy by Selecting for Favourable Functional, Phenotypic and Metabolic Profiles
To see full session details, download the full event guide
Rogier Reijmers, Principal Scientist, Lumicks
11.30 Optimizing recombinant proteins and cytokines for large-scale commercial manufacturing
To see full session details, download the full event guide
Ezequiel Zylberberg, VP Product Development & Planning, Akron Biotech
12.00 Enhancing the Safety and Efficacy of CAR-T via Regulation of CAR Expression
To see full session details, download the full event guide
Yoav Ben Yaacov, Co-Founder & CEO, CTG-Pharma
12.00 Discussing ‘Gold Standards’ and Innovations in Assay Development
To see full session details, download the full event guide
Eric Alonzo, Associate Director, Analytical Development, bluebird bio
12.00 Can we afford a Cure ? - Payer’s
Perspectives on Value Based Agreements & Innovative Contracting to Reimburse Cell & Gene Therapies
To see full session details, download the full event guide
Omar Ali, Visiting Lecturer, Value Based Pricing & Former Adviser to NICE, University of Portsmouth
12:30 pm Lunch & Networking
Research & Development
Translation & Clinical
Manufacturing & Commercialisation
Next-Generation Gene Engineering
& Non-Viral Delivery
Clinical Development for Allogeneic Therapies
Commercial Strategy for Seamless Cell Immunotherapy Delivery in the EU
13.00 Sharing Innovations in Non-Viral Vector Engineering
To see full session details, download the full event guide
Alper Kursunel, Postdoctoral Researcher, Max-Delbrück-Center for Molecular Medicine
13.00 Identifying the Best Allogeneic Cell and Donor Populations
To see full session details, download the full event guide
Michael Koslowski, CEO, GammaDelta Therapeutics
13.00 Sharing Experience of Point-of-Care CAR T-Cell Production Using a Closed Semi-Automatic Bioreactor
To see full session details, download the full event guide
Maria Castellà, Production Manager, Immunotherapy Platform, Hopital Clinic-BST
13:30 Enabling complex cell engineering
with a non-viral delivery platform for cell therapy manufacture
To see full session details, download the full event guide
Shirley O’Dea, CSO, Avectas
13:30 Biomarkers to accelerate CART T-cell development
To see full session details, download the full event guide
Akanksha Gupta, Head, Immunology, Biomarker Solution Center, Covance
13.30 Challenges and Solutions for GMP CAR T cell manufacturing
To see full session details, download the full event guide
Andrew Kaiser, R&D Senior Manager Cell&Gene Immunotherapy, Miltenyi Biotec
14:00 Generating CAR T Cells in Vivo
To see full session details, download the full event guide
Christian Buchholz, Group Leader, Paul-Ehrlich-Institut
14:00 Exploiting a Single Receptor for Solid Tumour and Haematological Conditions in Autologous
and Allogeneic Settings
To see full session details, download the full event guide
David Gilham, CSO, Celyad Oncology
14:00 Managing the Chain of Identity for Seamless, Patient-Centric Supply
To see full session details, download the full event guide
William Shingler, Senior Director, Patient & Cell Management, Autolus Ltd
14:30 Panel Discussion: Future applications of next-generation gene editing for CAR-T
To see full session details, download the full event guide
Marco Alessandrini, CTO, Antion Biosciences
Cécile Bauche, Founder, EVP, CSO, Aratinga.bio
Sarah Meeks, VP Business Development, MaxCyte
14:30 Clinical Development of the Allogeneic PBCAR-T Cells Demonstrating Persistence and Investigating its Correlation with Efficacy
To see full session details, download the full event guide
Christopher Heery, CMO, Precision Biosciences
14:30 Considerations and Best Practice in Delivering Cell Immunotherapies with a European Healthcare Authority
To see full session details, download the full event guide
Valeria Judkowski, Senior Director, Quality Assurance Head Site Qualification EU, Kite: A Gilead Company
3:00 pm Afternoon Refreshments & Tech Slam
Research & Development
Translation & Clinical
Manufacturing & Commercialisation
Optimising CAR-TCR Design for Improved Efficacy, Safety & Persistence
Clinical Outcomes & Toxicity Management to Minimise Additional Treatment
Advancing Manufacturing & Automation for High Quality Cell Therapy Products at Scale
16:00 The Affinity-Avidity Conundrum: Optimising Receptor-Target Interactions for Improved Safety and Efficacy
To see full session details, download the full event guide
Leah Sibener, Co-Founder & Head of Therapeutic Discovery, 3T Biosciences
16:30 Defining Therapeutic Endpoints for Rapid Assessment of Clinical Benefit
To see full session details, download the full event guide
Amit Patel, Consultant, Cellular Therapies and Stem Cell Transplantation, The Christie NHS
16:00 Developing CD8-Independent, Next-Generation TCRs for Solid Tumour Indications
To see full session details, download the full event guide
Ali Mohamed, VP, CMC, Immatics Biotechnologies
16:30 Engineering Strategies for Fitness in the Solid Tumour Microenvironment
To see full session details, download the full event guide
Francesco Marincola, CSO, Refuge Biotech
16:30 Sharing Experience of Clinical
Development of CAR-T in Liquid and Solid Tumour Indications
To see full session details, download the full event guide
Hong Ma, SVP, Clinical Development, CARsgen Therapeutics
16:30 Moving to Commercial Readiness with an Analytical Dedicated Platform for T-cell Therapies
To see full session details, download the full event guide
Jef Pinxteren, Director of Process and Analytical Development, Catalent Cell and Gene Therapy
17:00 Optimising T Cell Metabolism to Enhance Persistence in Solid Tumours
To see full session details, download the full event guide
Ramon Klein Geltink, Investigator, British Columbia Children’s Hospital
17:00 Discussing Success in Pre-Conditioning and Toxicity Management for Safe and Effective Therapeutic Delivery
To see full session details, download the full event guide
Adrian Bot, VP, Translational Medicine, Kite: A Gilead Company
17.00 Discussing Innovations in CAR-T
Manufacturing Platforms through Iterative Analysis and Improvement
To see full session details, download the full event guide
Steven Feldman, Director Manufacturing & Process Development, Stanford School of Medicine